Craig Brown, MD
Pulmonary Disease · Gainesville, GANPI 1063680882
Payments from drug & device makers
What this record shows
This record is dominated by education: $3,089 of the $4,705 with a category attached, or 65.7%. Intuitive Surgical accounts for 87.0% of it on its own, with 11 other manufacturers making up the rest. That places this record below the midpoint for pulmonary disease clinicians in GA, where the typical reported total is $3,789.
Across 33 payments — averaging $142.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$213
- United Therapeutics Corporation$127
- Electromed, Inc.$53
- Insmed, Inc.$43
- Genentech USA, Inc.$40
- plus $136 from 6 others
What the payments were for
- Travel & lodging$1,04022%
- Food & beverage$57612%
- Education$3,08966%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $4,092 |
| GSK | 2 | $213 |
| United Therapeutics Corporation | 2 | $127 |
| Electromed, Inc. | 7 | $53 |
| Insmed, Inc. | 2 | $43 |
| Genentech USA, Inc. | 1 | $40 |
| Boehringer Ingelheim | 1 | $34 |
| CSL Behring | 2 | $29 |
| Philips North America LLC | 1 | $20 |
| AbbVie | 1 | $20 |
| Advanced Respiratory, Inc | 1 | $19 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,002
- TYVASO$125
- NUCALA$118
How this compares
$4,705 in reported general payments places this provider in the 50th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 692 | $655,314 |
| OpsumitMacitentan | 29 | $473,752 |
| AdempasRiociguat | 20 | $258,800 |
| OfevNintedanib Esylate | 17 | $212,395 |
| Breo ElliptaFluticasone/Vilanterol | 370 | $199,012 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 157 | $143,986 |
| NucalaMepolizumab | 12 | $131,016 |
| Spiriva RespimatTiotropium Bromide | 137 | $116,285 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 120 | $85,839 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 114 | $84,833 |
| Dupixent SyringeDupilumab | 22 | $82,310 |
| SymbicortBudesonide/Formoterol Fumarate | 154 | $47,921 |
| Spiriva HandihalerTiotropium Bromide | 51 | $45,439 |
| Incruse ElliptaUmeclidinium Bromide | 88 | $34,195 |
| Advair HfaFluticasone Propion/Salmeterol | 52 | $26,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $213 | $1,127,6341,358 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $34 | $430,997291 claims |
| BayerAdempas | $14 | $258,80020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Gainesville
- Vivek SambharaGainesville$417K
- Lawrence McDermottSavannah$963K
- Chad MillerAustell$382K
- Nehal BhattAthens$371K
- Maria MascoloRincon$358K
- Colin SwensonAtlanta$255K
- David MillerDecatur$206K
- Michael MullinsSavannah$132K
- Hitendra PatelMarietta$104K
- Eric FlenaughAtlanta$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.